Scientist, Neuroscience Program
Ottawa Hospital Research Institute

Neurologist, Neurology, Medicine
The Ottawa Hospital

Co-Director, Deep Brain Stimulation Program (Movement Disorders)
uOttawa Brain and Mind Research Institute

Associate Professor, Medicine, Neurology
University of Ottawa

My clinical research interests include clinical trial methodology, development of new treatment for non-motor symptoms in Parkinson’s disease as well as biomarker development in neurodegenerative parkinsonisms.

Dr. Tiago Mestre is a physician with The Ottawa Hospital and a researcher with the Ottawa Hospital Research Institute and the uOttawa Brain and Mind Research Institute. He is currently leading the implementation of programs for treatment of advanced PD patients at the Ottawa Hospital including Deep Brain Stimulation and Duodopa. He leads a clinical research program in Movement Disorders focused in the area of drug development in areas of need, development of better outcomes for clinical trials and optimization of drug development from a preclinical to a first-in-human and confirmatory stages, fostering collaborations intra and extra-mural with basic neuroscience and clinical research groups. The different lines of research include the conduction of investigator-initiated clinical trials in Parkinson Disease, the study of placebos and expectation of benefit using Parkinson Disease as a model, identification of clinical phenotypes applicable to clinical research in PD and development of prediction rules for incident PD. He is interested in the development of novel paradigm of care delivery in PD, transposable to other chronic neurodgenerative disorders. As leader of the Deep Brain Stimulation program is interested in the development of novel paradigms of stimulation.

Outeiro TF, Mestre TA., Synuclein Meeting 2019: where we are and where we need to go, J Neurochem, Volume 150, Issue 5, 462-266 (September 2019)
Open Access, 10.1111/jnc.14825  PMID: 3144104

Mestre TA, Guttman M., The dawn of a new era for neurodegenerative disorders: Huntington's disease leading the way., Mov Disord. (August 2019)
10.1002/mds.27826 PMID: 31433876

Kessler D, Hauteclocque J, Grimes D, Mestre T, Côtéd D, Liddy C., Development of the Integrated Parkinson's Care Network (IPCN): using co-design to plan collaborative care for people with Parkinson's disease., Qual Life Res., Volume 28, Issue 5, 1355-1364 (May 2019) 10.1007/s11136-018-2092-0 PMID: 30600492

Mestre TA, Recent advances in the therapeutic development for Huntington disease., Parkinsonism Relat Disord, Volume Feb, Issue 59, 125-130 (December 2018) 10.1016/j.parkreldis.2018.12.003 PMID: 30616867

Mestre TA, Assessing and managing Parkinson’s disease from home: A 21st century vision closer to reality", Mov Dis., Volume 33, Issue 9, 1407 (July 2018)
10.1002/mds.112 PMID: 30216537

Amyotrophic lateral sclerosis; Huntington's; Parkinson's

Clinical trials; Imaging